IMROZ Study
Sanofi’s Sarclisa Achieves First-in-Class Win, Poised to Surpass J&J in Multiple Myeloma Treatment
Sarclisa, Sanofi, multiple myeloma, J&J, ASCO, IMROZ study, anti-CD38 therapy, VRd, transplant-ineligible patients
Actionable Insights Powered by AI
Sarclisa, Sanofi, multiple myeloma, J&J, ASCO, IMROZ study, anti-CD38 therapy, VRd, transplant-ineligible patients